Yossepowitch Ofer, Lifshitz David A, Dekel Yoram, Ehrlich Yaron, Gur Uri, Margel David, Livne Pinhas M, Baniel Jack
Institute of Urology, Rabin Medical Center, Petah Tikva, Israel.
J Urol. 2005 Mar;173(3):890-3. doi: 10.1097/01.ju.0000147747.89028.64.
Conservative treatment of upper urinary tract tumors has been popularized during the last decade. Like in bladder cancer management, localized adjuvant therapy has been advocated to reduce the risk of disease recurrence or progression. In this study we tested the feasibility of creating vesicoureteral reflux (VUR) using a Double-J stent (Medical Engineering Corp., New York, New York) as a measure of efficacy for intravesical adjuvant treatment of the ureter and renal collecting system.
The cohort included 100 consecutive patients in whom a Double-J stent was inserted for renal obstruction. All the patients underwent cystography in the supine position by retrograde filling of the bladder with a 50% dilute solution of 300 mgI/ml iopromide in serial increments of 50 ml up to a maximum of 350 ml. A total of 41 patients underwent cystography immediately following stent insertion (early group) and 59 patients with indwelling stents underwent cystography before further endourological intervention (late group). The presence of VUR and the level along the ureter and renal collecting system were assessed fluoroscopically.
Overall VUR was detected in 56 patients (56%), specifically 11 of the 41 (27%) in the early group and 45 of the 59 (76%) in the late group (p <0.001). There was no correlation between stent diameter or length and VUR, or between patient sex, age or particular side and the likelihood of reflux. Mean minimal intravesical volume required to obtain reflux was 171 +/- 11 ml, which was significantly higher in the early (255 +/- 21 ml) than in the late (146 +/- 11 ml) cystogram group. In 24 of the 56 patients (43%) with VUR, there was complete visualization of the entire ureter and renal collecting system. However, 15 patients (26%) had opacified renal pelves and calices without concomitant visualization of the ureters, whereas 7 patients (31%) had reflux to the ureter without opacification of the renal pelvis.
VUR is not a guaranteed consequence of Double-J stent placement. Therefore, when upper urinary tract instillation with the Double-J technique is considered, a cystogram should be performed first to confirm the occurrence of reflux, determine the intravesical volume required to induce reflux and ascertain that the pertinent section of the ureter or pelvicaliceal system from which the tumor was initially removed is opacified during study. An interval that remains to be defined should be allowed between stent insertion and VUR assessment.
在过去十年中,上尿路肿瘤的保守治疗已得到推广。与膀胱癌治疗类似,局部辅助治疗被提倡用于降低疾病复发或进展的风险。在本研究中,我们测试了使用双J支架(医疗工程公司,纽约,纽约)制造膀胱输尿管反流(VUR)作为输尿管和肾集合系统膀胱内辅助治疗疗效衡量指标的可行性。
该队列包括100例连续因肾梗阻而插入双J支架的患者。所有患者均在仰卧位通过用300mgI/ml碘普罗胺50%稀释溶液逆行充盈膀胱进行膀胱造影,每次增量50ml,最大量达350ml。41例患者在支架插入后立即进行膀胱造影(早期组),59例留置支架患者在进一步的腔内泌尿外科干预前进行膀胱造影(晚期组)。通过荧光镜检查评估VUR的存在以及沿输尿管和肾集合系统的水平。
共56例患者(56%)检测到总体VUR,具体而言,早期组41例中有11例(27%),晚期组59例中有45例(76%)(p<0.001)。支架直径或长度与VUR之间、患者性别、年龄或特定侧别与反流可能性之间均无相关性。产生反流所需的平均最小膀胱内体积为171±11ml,早期膀胱造影组(255±21ml)显著高于晚期组(146±11ml)。在56例有VUR的患者中,24例(43%)整个输尿管和肾集合系统完全显影。然而,15例患者(26%)肾盂和肾盏显影但输尿管未同时显影,而7例患者(31%)反流至输尿管但肾盂未显影。
VUR并非双J支架置入的必然结果。因此,当考虑采用双J技术对上尿路进行灌注时,应首先进行膀胱造影以确认反流的发生,确定诱导反流所需的膀胱内体积,并确定在研究过程中最初切除肿瘤的输尿管或肾盂肾盏系统的相关部分显影。在支架插入和VUR评估之间应留出一个有待确定的间隔时间。